49 Statistical Hypothesis .................................................................................................... 49 8.1.1 Primary Efficacy Endpoints ...................................................................................... 49 8.1.2 Secondary Efficacy Endpoint ................................................................................... 49 Abbreviated Title: mRNA-Based, Cancer Vaccine Version Date: January 23, 2019 7 Sample Size De termination........................................................................................... 49 Populations for Analyses ..............................................................................................